X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020 8:00 AM ESTWHIM Phase 2 data published in Blood - the Official Journal of the American Society of Hematology
Granted Fast Track Designation by FDA for mavorixafor in WHIM syndrome
Key leadership appointments including CSO and Board Director
Conference call today at 8:30 a.m. ET
BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) --... More



